CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (USD $) In Thousands, except Share data	3 Months Ended		9 Months Ended
	Sep. 30, 2011	Sep. 30, 2010	Sep. 30, 2011	Sep. 30, 2010
Laboratory services:
Drugs-of-abuse testing services	$ 10,781	$ 10,390	$ 31,227	$ 29,346
Clinical & other laboratory services	8,885	7,928	25,993	22,396
Clinical trial services	2,375	2,358	7,234	5,228
Product sales	5,537	5,123	16,781	15,175
Total revenues	27,578	25,799	81,235	72,145
COST OF REVENUES:
Cost of services	13,975	12,951	40,550	36,535
Cost of sales	2,233	2,036	6,788	6,357
Total cost of revenues	16,208	14,987	47,338	42,892
GROSS PROFIT	11,370	10,812	33,897	29,253
OPERATING EXPENSES:
Selling, general and administrative	8,633	8,394	26,538	24,058
Research and development	668	576	1,884	1,698
Total operating expenses	9,301	8,970	28,422	25,756
INCOME FROM OPERATIONS	2,069	1,842	5,475	3,497
OTHER INCOME (EXPENSE):
Interest expense	(7)	(1)	(49)	(2)
Other income (expense)	16	(33)	89	28
Total other income (expense)	9	(34)	40	26
INCOME BEFORE INCOME TAX EXPENSE	2,078	1,808	5,515	3,523
INCOME TAX EXPENSE	(758)	(660)	(2,013)	(1,286)
NET INCOME	$ 1,320	$ 1,148	$ 3,502	$ 2,237
BASIC EARNINGS PER COMMON SHARE (in dollars per share)	$ 0.15	$ 0.13	$ 0.40	$ 0.26
DILUTED EARNINGS PER COMMON SHARE (in dollars per share)	$ 0.15	$ 0.13	$ 0.39	$ 0.25
WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING:
Basic (in shares)	8,851,511	8,718,772	8,849,874	8,686,962
Diluted (in shares)	9,040,569	8,963,969	9,045,038	8,922,443